Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US
The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.
Search
Venu Thatikonda
An in-depth look into working life at Boehringer Ingelheim with Venu Thatikonda.
A Few Ways We Support US Livestock | Boehringer Ingelheim US
Click here to view the Boehringer Ingelheim infographic on how we support livestock across the USA in partnership with the USDA's agriculture department.
Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Board of Managing Directors
Read more about Boehringer Ingelheim's board of managing directors, with information on all five members and their respective responsibilities.
More Potential
More Potential
Office Hours Program | Partnering
Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.
Oncology Partnering Interests | Boehringer Ingelheim US
Click here to view our range of downloads on Boehringer Ingelheim's oncology & cancer immunology partnering interests.
Press Releases | Boehringer Ingelheim US
Press Releases
Newsletter Subscription Confirmation
Newsletter : Thank you for subscribing
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Breathless Ballad
Breathless Ballad
3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US
Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.
Sant Cugat del Vallès (Barcelona)
Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US
Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Valerie Nock
My career challengeFunctional Areas at Boehringer Ingelheim
Our Businesses
Our Businesses
Management Rotation | Academic Programs
Management Rotation Program